Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.

Rebecca C Arend, Hannah M Beer,Yael C Cohen,Suzanne Berlin,Michael J Birrer,Susana M Campos,Tamar Rachmilewitz Minei,Dror Harats,Jaclyn A Wall,McKenzie E Foxall,Richard T Penson

Gynecologic Oncology（2020）

引用 15|浏览49

暂无评分

摘要

•VB-111 has a dual mechanism targeting tumor vasculature and inducing anti-tumor immune effects turning “cold” tumors “hot”.•VB-111 with paclitaxel had a 58% CA-125 response rate that correlated with a survival benefit.•VB-111 in combination with paclitaxel had a similar OS effect and better CA-125 response than in the AURELIA study.•VB-111 was safe and well tolerated.

查看译文

关键词

VB-111,Gene therapy,Anti-angiogenic,Platinum-resistant ovarian cancer,Immunotherapeutic,Platinum-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要